Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity

Colorectal cancer is considered a non‐immunogenic malignany. One strategy to augment the immunogenicity of such tumours is represented by the expression of costimulatory molecules by gene transfer. Using transfected variants of the human colorectal cancer cell line SW480 we tested various costimulatory molecules (CD80, CD86, CD54) and a class II major histocompatibility complex (MHC) allele (HLA‐DR3) alone or in combination on their ability to support primary T‐lymphocyte activation in vitro . Expression of CD80 or CD86 similarly as the combination of both was not sufficient to induce proliferation of human allogeneic T cells. Expression of CD54 together with CD80 strongly augmented the costimulatory function of CD80, as observed in the presence of a CD3 monoclonal antibody (mAb), but did not lead directly to a T‐cell response against modified tumour cells. Importantly, SW480 cells coexpressing CD54, CD80 and the HLA‐DR3 allele effectively promoted T‐lymphocyte proliferation. Moreover, the use of such CD54 + /CD80 + /HLA‐DR3 + SW480 variants for repetitive stimulations resulted in the generation of T‐cell lines predominantly composed of CD8 + T cells exhibiting class I MHC restricted cytolytic activity towards untransfected SW480 tumour cells. This demonstrates that the generation of immunogenic tumour cell variants, i.e. for the use as cellular vaccines, requires multiple genetic alterations in the case of non‐immunogenic human tumours cells, such as colorectal cancer cells.